Search results for "Lemi"

showing 10 items of 513 documents

The Small Size and Superficial Location Suggest That Laparoscopic Partial Nephrectomy Is the First Choice for the Treatment of Juxtaglomerular Cell T…

2021

BackgroundJuxtaglomerular cell tumor (JGCT) is a very rare disease, and surgical resection is the only possible way to cure this tumor. Open nephrectomy and partial nephrectomy have been reported to manage JGCTs with excellent results in the previous reviews. Laparoscopic surgery has been popularized in recent years, while critical issues associated with laparoscopic surgical management have been seldom reported. We summarized the JGCTs in our center to discover the optimal surgical management and its anatomic foundation.MethodsIn this retrospective study, we enrolled a total of 14 JGCT patients. All patients received surgeries and were followed up for up to 11 years. We mainly summarized t…

AdenomaAdultMaleLaparoscopic surgerymedicine.medical_specialtyAdolescentEndocrinology Diabetes and Metabolismmedicine.medical_treatmentsuperficial location030204 cardiovascular system & hematologyNephrectomyPlasma renin activityDiseases of the endocrine glands. Clinical endocrinologysmall sizeYoung Adult03 medical and health sciencesEndocrinologyPostoperative Complications0302 clinical medicinemedicineHumansCarcinoma Renal CellOriginal ResearchAgedRetrospective Studieslaparoscopic partial nephrectomybusiness.industryRetrospective cohort studyjuxtaglomerular cell tumorsMiddle AgedRC648-665medicine.diseaseMagnetic Resonance ImagingKidney NeoplasmsHypokalemiaNephrectomySurgeryBlood pressure030220 oncology & carcinogenesisFemaleLaparoscopymedicine.symptombusinessJuxtaglomerular cell tumorlaparoscopic ultrasoundRare diseaseFrontiers in Endocrinology
researchProduct

Hypermineralocorticoidism and hypertension

1971

Die mit Hypokaliamie, Uberproduktion von Mineralocorticoiden (Aldosteron und/oder Corticosteron und Desoxycorticosteron) und Aktivitatsanderungen des Renin-Angiotensinsystems einhergehenden Hochdrucksformen werden beschrieben. Sie lassen sich nach willkurlich gewahlten biochemischen Kriterien in drei Gruppen einteilen: a) Hypermineralocorticoidismus mit Reninsuppression und Aldosteronismus, b) Hypermineralocorticoidismus mit Reninund Aldosteronsuppression und c) Hypermineralocorticoidismus mit erhohtem Plasmarenin und Aldosteronismus. Jede dieser Gruppen besteht aus mehreren Syndromen, die sich durch ihr adrenocorticales Sekretionsmuster und/oder ihre morphologischen Nebennierenrindenverand…

AdenomaGynecologymedicine.medical_specialtyAdrenocortical HyperfunctionHyperplasiabusiness.industryAdrenal Gland NeoplasmsHypokalemiaGeneral MedicineRenal Artery ObstructionDexamethasoneDiagnosis DifferentialHypertension MalignantMineralocorticoidsHyperaldosteronismHypertensionReninDrug DiscoverymedicineHumansMolecular MedicinebusinessAldosteroneCushing SyndromeGenetics (clinical)Klinische Wochenschrift
researchProduct

Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease

2011

The aim of this paper is to review the latest data on the pharmacological modulation of asymmetric dimethylarginine in human disease. When the terminal nitrogens of the guanidine portion of an arginine become methylated through the action of N-methyl transferases, two chemically close, but physiologically different amino acids are synthesized: symmetric and asymmetric dimethylarginine. The vascular origin of asymmetric dimethylarginine and its inhibitory activity on endothelial nitric oxide synthase give it an important role in certain diseases in which microcirculation is compromised: hypertension, atherosclerosis, inflammatory bowel disease, and diabetes. This review discusses the role th…

Adrenergic Antagonistsmedicine.medical_specialtyAngiotensinsNitric Oxide Synthase Type IIIArginineHypercholesterolemiaPeroxisome Proliferator-Activated ReceptorsHyperhomocysteinemiaReceptors Cytoplasmic and NuclearPeroxisome proliferator-activated receptorPharmacologyArginineBiochemistryNitric oxideDiabetes Complicationschemistry.chemical_compoundInternal medicineDrug DiscoveryAdrenergic antagonistmedicineHumansVascular DiseasesPharmacologychemistry.chemical_classificationVascular diseaseMicrocirculationOrganic Chemistrymedicine.diseaseAngiotensin IIEndocrinologychemistryHypertensionMolecular MedicineKidney DiseasesFarnesoid X receptorHydroxymethylglutaryl-CoA Reductase InhibitorsAsymmetric dimethylarginineCurrent Medicinal Chemistry
researchProduct

Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features

2020

Abstract Background and aims Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by extremely elevated plasma levels of low density lipoprotein cholesterol (LDL-C) and high risk of premature atherosclerotic cardiovascular disease (ASCVD). HoFH is caused by pathogenic variants in several genes, such as LDLR, APOB and PCSK9, responsible for autosomal dominant hypercholesterolemia (ADH), and LDLRAP1 responsible for autosomal recessive hypercholesterolemia (ARH). Aim of this study was the review of the clinical and molecular features of patients with HoFH identified in Italy from 1989 to 2019. Methods Data were collected from lipid clinics and laboratories, …

Adult0301 basic medicinemedicine.medical_specialtyCandidate geneCandidate geneGenotype-phenotype correlationApolipoprotein BCandidate genes; Genotype-phenotype correlations; Homozygous familial hypercholesterolemia; Pathogenic variantsHomozygous familial hypercholesterolemiaGenotype-phenotype correlationsFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosityCandidate genesHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansbiologybusiness.industryPCSK9HomozygoteGenetic disorderPathogenic variantsCandidate genes; Genotype-phenotype correlations; Homozygous familial hypercholesterolemia; Pathogenic variants;medicine.diseasePhenotype030104 developmental biologyEndocrinologyItalyReceptors LDLAutosomal Recessive HypercholesterolemiaMutationLDL receptorbiology.proteinlipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular Medicinebusiness
researchProduct

Influence of LDL receptor gene mutations and the R3500Q mutation of the apoB gene on lipoprotein phenotype of familial hypercholesterolemic patients …

2003

Few data are available on genotype-phenotype interactions among familial hypercholesterolemia (FH) patients in South European populations and there are no data about the influence of R3500Q mutation on lipoprotein phenotype compared to low-density lipoprotein receptor (LDLR) mutations. The objective of the study is to analyze the influence of mutations in the LDLR and apolipoprotein B (apoB) genes on lipoprotein phenotype among subjects clinically diagnosed of FH living in East Spain. In all, 113 FH index patients and 100 affected relatives were studied. Genetic diagnosis was carried out following a protocol based on Southern blot and PCR-SSCP analysis. A total of 118 FH subjects could be c…

AdultAdolescentApolipoprotein BHypercholesterolemiaPopulationMutation MissenseFamilial hypercholesterolemiaBiologymedicine.disease_causechemistry.chemical_compoundGeneticsmedicineHumansMissense mutationeducationGenetics (clinical)Apolipoproteins BGeneticsMutationeducation.field_of_studyCholesterolMiddle Agedmedicine.diseaseEuropePhenotypeReceptors LDLchemistryLDL receptorbiology.proteinlipids (amino acids peptides and proteins)LipoproteinEuropean Journal of Human Genetics
researchProduct

Risk factors, atrial fibrillation and thromboembolic events.

2008

AIM: The aim of this study was to evaluate the relation between risk factors for atrial fibrillation (AF) and thromboembolic complications. METHODS: We studied 480 patients (mean age: 71.2+/-11.6 years): 240 with paroxysmal AF, 240 with permanent AF. The association between AF and the presence of risk factors, cardiac and systemic disease was observed and the correlation with the occurrence of complications analyzed. RESULTS: Patients with AF had a high prevalence of the following conditions: hypertension, hypertensive heart disease (HHD), coronary artery disease, hyperthyroidism. Thromboembolism was observed in 26.6% of the patients. A correlation between the occurrence of a thromboembolic…

AdultAged 80 and overMaleHypercholesterolemiaSmokingFibrinogenMiddle Agedatrial fibrillation risk factorsCohort StudiesDiabetes ComplicationsYoung AdultRisk FactorsThromboembolismAtrial FibrillationHypertensionHumansFemaleObesityAgedInternational angiology : a journal of the International Union of Angiology
researchProduct

Effect of histamine and histamine analogues on human isolated myometrial strips.

1992

1. The effect of histamine and histamine H1- and H2-receptor agonists on isolated myometrium strips of premenopausal women has been examined. The effect of acetylcholine was also determined. 2. Histamine, 2-pyridylethylamine, 4-methylhistamine and acetylcholine, but not dimaprit, produced a concentration-related contractile response in human isolated myometrial strips. Histamine also produced a further contraction in human isolated myometrial strips precontracted with KCl (55 mM). 3. The contractile response to histamine was antagonized by the histamine H1-receptor antagonist, clemizole (0.1 microM) but was potentiated by the histamine H2-receptor antagonist, ranitidine (10 microM). Clemizo…

AdultAtropinemedicine.medical_specialtyPyridinesMuscle RelaxationHistamine H1 receptorRanitidineHistamine agonistPotassium ChlorideHistamine Agonistschemistry.chemical_compoundHistamine receptorUterine ContractionHistamine H2 receptorInternal medicinemedicineHumansPharmacologyDose-Response Relationship DrugMethylhistaminesMuscle SmoothMiddle AgedDimapritAcetylcholineClemizoleEndocrinologyMuscle relaxationchemistryMyometriumBenzimidazolesFemaleHistamineHistamineResearch ArticleBritish journal of pharmacology
researchProduct

Increased thromboxane biosynthesis in type IIa hypercholesterolemia.

1992

BACKGROUND Increased platelet thromboxane (TX)A2 production has been described in type IIa hypercholesterolemia. To verify the relevance of these capacity-related measurements to the actual rate of TXA2 biosynthesis in vivo, we studied the urinary excretion of its major enzymatic metabolites in 46 patients with type IIa hypercholesterolemia and 20 age-matched controls. METHODS AND RESULTS Urinary 11-dehydro-TXB2 and 2,3-dinor-TXB2 were measured by previously validated radioimmunoassays. The excretion rate of 11-dehydro-TXB2 was significantly (p less than 0.001) higher in patients (68.7 +/- 35.1 ng/hr, mean +/- SD) than in controls (22.4 +/- 9.4 ng/hr), with metabolite excretion greater tha…

AdultBlood PlateletsMalemedicine.medical_specialtySimvastatinThromboxaneMetaboliteHypercholesterolemiaExcretionchemistry.chemical_compoundThromboxane A2Physiology (medical)Internal medicinemedicineHumansPlateletPlatelet activationLovastatinAgedbiologyAspirinDose-Response Relationship Drugbusiness.industryCholesterolAnticholesteremic AgentsMiddle AgedEndocrinologychemistrySimvastatinbiology.proteinlipids (amino acids peptides and proteins)FemaleCyclooxygenaseCardiology and Cardiovascular Medicinebusinessmedicine.drugCirculation
researchProduct

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematolog…

2006

Abstract Purpose: LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle. Experimental Design: Fifteen patients (median age, 63 years; range, 42-87 years) with acute myeloid leukemia (13 patients), acute lymphocytic leukemia (1 patient), or myelodysplastic syndrome (1 patient) were treated with LBH589 at the following dose levels (mg/m2): 4.8 (3 patients), 7.2 (3 patients), 9.0 (1 patient), 11.5 (3 patient), and 14.0 (5 patients). The levels of histone acetylation were measured using quantitative flow cytometry and plasm…

AdultCancer ResearchIndolesMaximum Tolerated Dosemedicine.drug_classApoptosisPharmacologyHydroxamic AcidsDrug Administration ScheduleHistonesStructure-Activity Relationshipchemistry.chemical_compoundPredictive Value of TestsPanobinostatAcute lymphocytic leukemiaPanobinostatBiomarkers TumormedicineHumansEnzyme InhibitorsAgedCell ProliferationAged 80 and overDose-Response Relationship Drugbusiness.industryHistone deacetylase inhibitorArea under the curveQTcF ProlongationMyeloid leukemiaMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHypokalemiaHistone Deacetylase InhibitorsLeukemiaTreatment OutcomeOncologychemistryCinnamatesLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseInjections IntravenousImmunologymedicine.symptombusinessFollow-Up StudiesClinical Cancer Research
researchProduct

Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema

2005

BACKGROUND: Abdominal edema attacks in patients with hereditary angioedema are often extremely painful, associated with vomiting and diarrhea, and have a high potential for causing recurrent disability of the patient. STUDY DESIGN AND METHODS: Intraindividual comparison of retrospective data in 75 hereditary angioedema patients comprising 4,834 abdominal attacks treated with C1 inhibitor concentrate versus 17,444 untreated abdominal attacks. RESULTS: The mean duration of abdominal attacks was 92.0 hours (SD, 40.8 hr) when untreated compared to 39.9 hours (SD, 30.0 hr) when treated. Patients reported a mean maximal pain score of 8.6 (SD, 1.7; range, 1-10) for untreated attacks compared to 4.…

AdultDiarrheaAbdominal painTime FactorsAdolescentVomitingHypovolemiaImmunologyUnconsciousnessComplement C1 Inactivator ProteinsDrug Administration ScheduleInjectionsC1-inhibitorEcallantideHypovolemiaEdemamedicineHumansImmunology and AllergyAngioedemaChildAdverse effectSerpinsRetrospective StudiesDose-Response Relationship Drugbiologybusiness.industryInfantHematologymedicine.diseaseAbdominal PainTreatment OutcomePatient SatisfactionChild PreschoolAnesthesiaHereditary angioedemaVomitingbiology.proteinmedicine.symptombusinessComplement C1 Inhibitor ProteinBed Restmedicine.drugTransfusion
researchProduct